Compare Arqit Quantum Inc (ARQQ) vs Illumina, Inc. (ILMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arqit Quantum Inc vs Illumina, Inc. — how do they compare? Arqit Quantum Inc trades at $18.86 (market cap $332.04M), while Illumina, Inc. trades at $189.67 (market cap $28.78B). The key difference: Illumina, Inc. is far larger — about 86.7× Arqit Quantum Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | ILMN | |
|---|---|---|
Market Cap | $332.04M | $28.78B |
Sector | Technology | Health |
52-Week High | $58.27 | $194.33 |
52-Week Low | $11.78 | $91.00 |
Enterprise Value | $305.35M | $30.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.
Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.
Illumina (ILMN) trades at $190.20, down 1.84% on the day but up significantly year-to-date with strong momentum. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reflect a turnaround with net income reaching $850 million in 2025 after previous losses. Recent news highlights product launches and leadership appointments, with the company scheduled to report Q2 2026 earnings on July 30, 2026.
The outlook remains positive with analyst consensus leaning bullish, though valuation multiples appear elevated. Key risks include competitive pressure from new entrants like Roche's Axelios sequencer and execution challenges in maintaining profitability growth. The upcoming earnings report will be critical for validating the current rally's sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
